spironolactone has been researched along with Heart Diseases in 51 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 9.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| "Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure." | 9.09 | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. ( Castaigne, A; Cody, R; Palensky, J; Perez, A; Pitt, B; Remme, WJ; Wittes, J; Zannad, F, 1999) |
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 7.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| "Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents." | 7.77 | Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011) |
| " Further, this is the first study demonstrating amiloride could also improve myocardial fibrosis." | 5.17 | Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. ( MacWalter, RS; McSwiggan, S; Ogston, SA; Struthers, AD; Sze, KY; Wong, KY; Wong, SY, 2013) |
| "Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure." | 5.09 | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. ( Castaigne, A; Cody, R; Palensky, J; Perez, A; Pitt, B; Remme, WJ; Wittes, J; Zannad, F, 1999) |
| "In this study, we examined whether spironolactone (SP) could inhibit doxorubicin (DOX)-induced cardiotoxicity in the rat heart." | 3.83 | Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. ( Chen, C; Dong, Z; Hou, T; Liu, G; Liu, Y; Wang, R; Zheng, S, 2016) |
| "Angiotensin II (Ang II) and aldosterone contribute to hypertension, oxidative stress and cardiovascular damage, but the contributions of aldosterone during Ang II-dependent hypertension are not well defined because of the difficulty to assess each independently." | 3.81 | Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. ( Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP, 2015) |
| "Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents." | 3.77 | Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011) |
| " We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice." | 3.76 | Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| " Angiotensin-converting enzyme inhibitor dosage and RAAS inhibition were greater in stage D, compared to stage C dogs." | 1.56 | Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease. ( Adin, D; Atkins, C; Kurtz, K; Papich, MG; Vaden, S, 2020) |
| "Spironolactone treatment prevented Th17 cell activation and increased numbers of forkhead box P3-positive cells relative to DOCA-salt rats." | 1.40 | Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. ( Alzamora, R; Amador, CA; Barrientos, V; Carrasco, L; Figueroa, F; González, M; Herrada, AA; Kalergis, AM; Michea, L; Peña, J; Valdés, S, 2014) |
| "Corticosterone or vehicle was injected twice daily in rats from 8 to 12 weeks of age." | 1.39 | Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. ( Hattori, T; Iwase, E; Miyachi, M; Murase, T; Murohara, T; Nagata, K; Ohtake, M; Takahashi, K; Tsuboi, K, 2013) |
| "Nandrolone decanoate treatment increased the QTc interval and reduced the parasympathetic indexes of HRV (RMSSD, pNN5 and high-frequency power) in sedentary and trained rats." | 1.39 | The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction. ( da H Silva, A; dos Santos, MC; Ferraz, EF; Marques Neto, SR; Nascimento, JH, 2013) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| " Patient demographic information was collected, as well as dosing regimens, use of other medications, and potassium concentrations." | 1.33 | Clinical experience with spironolactone in pediatrics. ( Buck, ML, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (52.94) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 6 (11.76) | 29.6817 |
| 2010's | 16 (31.37) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, GH | 2 |
| Adin, D | 1 |
| Kurtz, K | 1 |
| Atkins, C | 1 |
| Papich, MG | 1 |
| Vaden, S | 1 |
| Moffett, BS | 1 |
| Haworth, TE | 1 |
| Wang, Y | 1 |
| Afonso, N | 1 |
| Checchia, PA | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Hattori, T | 1 |
| Murase, T | 1 |
| Iwase, E | 1 |
| Takahashi, K | 1 |
| Ohtake, M | 2 |
| Tsuboi, K | 1 |
| Miyachi, M | 1 |
| Murohara, T | 1 |
| Nagata, K | 1 |
| Wong, KY | 1 |
| Wong, SY | 1 |
| McSwiggan, S | 1 |
| Ogston, SA | 1 |
| Sze, KY | 1 |
| MacWalter, RS | 1 |
| Struthers, AD | 1 |
| Amador, CA | 1 |
| Barrientos, V | 1 |
| Peña, J | 1 |
| Herrada, AA | 1 |
| González, M | 1 |
| Valdés, S | 1 |
| Carrasco, L | 1 |
| Alzamora, R | 1 |
| Figueroa, F | 1 |
| Kalergis, AM | 1 |
| Michea, L | 1 |
| Jeewandara, TM | 1 |
| Ameer, OZ | 1 |
| Boyd, R | 1 |
| Wyse, BF | 1 |
| Underwood, CF | 1 |
| Phillips, JK | 1 |
| Minas, JN | 1 |
| Thorwald, MA | 1 |
| Conte, D | 1 |
| Vázquez-Medina, JP | 1 |
| Nishiyama, A | 1 |
| Ortiz, RM | 1 |
| Liu, G | 1 |
| Liu, Y | 1 |
| Wang, R | 1 |
| Hou, T | 1 |
| Chen, C | 1 |
| Zheng, S | 1 |
| Dong, Z | 1 |
| Desai, A | 1 |
| Lea, WB | 1 |
| Kwak, ES | 1 |
| Luther, JM | 2 |
| Fowler, SM | 1 |
| Wang, Z | 2 |
| Ma, J | 1 |
| Fogo, AB | 2 |
| Brown, NJ | 2 |
| Bauer, R | 1 |
| Blain, A | 1 |
| Greally, E | 1 |
| Lochmüller, H | 1 |
| Bushby, K | 1 |
| MacGowan, GA | 1 |
| Straub, V | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Hori, Y | 1 |
| Yoshioka, K | 1 |
| Kanai, K | 1 |
| Hoshi, F | 1 |
| Itoh, N | 1 |
| Higuchi, S | 1 |
| Williams, RS | 1 |
| deLemos, JA | 1 |
| Dimas, V | 1 |
| Reisch, J | 1 |
| Hill, JA | 1 |
| Naseem, RH | 1 |
| Luo, P | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Brem, AS | 1 |
| Marques Neto, SR | 1 |
| da H Silva, A | 1 |
| dos Santos, MC | 1 |
| Ferraz, EF | 1 |
| Nascimento, JH | 1 |
| SANDERS, LL | 1 |
| MELBY, JC | 1 |
| RAAB, W | 1 |
| BARTOS, V | 1 |
| KVASNICKA, J | 1 |
| GROH, J | 1 |
| ERBEN, J | 1 |
| MOULINIER, B | 1 |
| TETE, R | 1 |
| COTTON, J | 1 |
| GIRARD, M | 1 |
| CLARK, E | 1 |
| Buck, ML | 1 |
| Vallon, V | 1 |
| Wyatt, AW | 1 |
| Klingel, K | 1 |
| Huang, DY | 1 |
| Hussain, A | 1 |
| Berchtold, S | 1 |
| Friedrich, B | 1 |
| Grahammer, F | 1 |
| Belaiba, RS | 1 |
| Görlach, A | 1 |
| Wulff, P | 1 |
| Daut, J | 1 |
| Dalton, ND | 1 |
| Ross, J | 1 |
| Flögel, U | 1 |
| Schrader, J | 1 |
| Osswald, H | 1 |
| Kandolf, R | 1 |
| Kuhl, D | 1 |
| Lang, F | 1 |
| Nehme, J | 1 |
| Mercier, N | 1 |
| Labat, C | 1 |
| Benetos, A | 1 |
| Safar, ME | 1 |
| Delcayre, C | 1 |
| Lacolley, P | 1 |
| Bufalari, A | 1 |
| Meloni, G | 1 |
| Babej, RM | 1 |
| Soyka, LF | 1 |
| Suzuki, M | 1 |
| Ogawa, K | 1 |
| Pitt, B | 1 |
| Zannad, F | 1 |
| Remme, WJ | 1 |
| Cody, R | 1 |
| Castaigne, A | 1 |
| Perez, A | 1 |
| Palensky, J | 1 |
| Wittes, J | 1 |
| Martinez, DV | 1 |
| Rocha, R | 1 |
| Matsumura, M | 1 |
| Oestreicher, E | 1 |
| Ochoa-Maya, M | 1 |
| Roubsanthisuk, W | 1 |
| Adler, GK | 1 |
| Vinogradov, AV | 1 |
| Sycheva, IM | 1 |
| Zhuravleva, IA | 1 |
| Zweifler, AJ | 1 |
| Esler, M | 1 |
| Schauer, J | 1 |
| Urbaszek, W | 1 |
| Hahn, S | 1 |
| Günther, K | 1 |
| Olesen, KH | 1 |
| Valentin, N | 1 |
| Raynaud, R | 1 |
| Brochier, M | 1 |
| Raynaud, P | 1 |
| Fauchier, JP | 1 |
| Havard, CW | 1 |
| Bordás, E | 1 |
| Bretter, E | 1 |
| Shah, S | 1 |
| Bezborod'ko, BN | 1 |
| Shekhunova, MI | 1 |
| Selivonenko, VG | 1 |
| Căruntu, M | 1 |
| Mihail, A | 1 |
| Oelert, H | 1 |
| Salvador, M | 1 |
| Thomas, C | 1 |
| Mazenq, M | 1 |
| Conté, J | 1 |
| Mériel, P | 1 |
| Lesbre, P | 1 |
| Savoie, LL | 1 |
| Jick, H | 1 |
| Gardell, C | 1 |
| Tuchweber, B | 1 |
| Hatakeyama, S | 1 |
| Kovacs, K | 1 |
| Kühn, P | 1 |
| Probst, P | 1 |
| Lenzi, F | 1 |
| Radó, J | 1 |
| Marosi, J | 1 |
| Takó, J | 1 |
| Dévényi, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)[NCT01882179] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Randomized Clinical Trial of Radiofrequency Ablation for Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction for Reduced Healthcare Utilization[NCT04327596] | 2 participants (Actual) | Interventional | 2021-01-25 | Terminated (stopped due to lack of enrollment) | |||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Exercise Intolerance in Elderly Diastolic Heart Failure[NCT00123955] | Phase 3 | 80 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
"Left ventricle measurements by MRI:~Mass/end diastolic volume ratio: g/ml" (NCT00123955)
Timeframe: Baseline, 9 month
| Intervention | g/ml (Mean) | |
|---|---|---|
| baseline | 9 month | |
| Placebo | 1.7 | 1.6 |
| Spironolactone | 1.8 | 1.7 |
Peak exercise VO2 (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | ml/kg/min (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | 9 months | |
| Placebo | 13.3 | 13.5 | 13.9 |
| Spironolactone | 13.5 | 13.6 | 13.8 |
"Echocardiography Doppler measurement of left ventricular diastolic function:~Early mitral annulus velocity (lateral) (Ea; cm/s)" (NCT00123955)
Timeframe: Baseline, 4 month and 9 month
| Intervention | cm/s (Mean) | ||
|---|---|---|---|
| baseline | 4 month | 9 month | |
| Placebo | 6.8 | 6.8 | 6.6 |
| Spironolactone | 7.0 | 7.0 | 7.4 |
"The Minnesota Living with Heart Failure Questionnaire (MLHF) is a self-administered disease-specific questionnaire for patients with Heart Failure, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on HRQoL, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25). The other eight items (of the total of 21) are only considered for the calculation of the total score.~Scale of 0-105:The higher the score the worse the heart failure related Quality of Life." (NCT00123955)
Timeframe: Baseline, 4 and 9 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 4 months | Final- 9 months | |
| Placebo | 28 | 29 | 25 |
| Spironolactone | 32 | 29 | 29 |
3 reviews available for spironolactone and Heart Diseases
| Article | Year |
|---|---|
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
NEUROGENIC MULTIFOCAL DESTRUCTION OF MYOCARDIAL TISSUE (PATHOGENIC MECHANISM AND ITS PREVENTION).
Topics: Adrenal Cortex Hormones; Catecholamines; Epinephrine; Heart Diseases; Hypoxia; Myocardial Infarction | 1963 |
[Aldosterone and aldosterone antagonists in surgery].
Topics: Adult; Aldosterone; Blood Volume; Brain Edema; Cardiac Surgical Procedures; Child; Digitalis Glycosi | 1971 |
3 trials available for spironolactone and Heart Diseases
| Article | Year |
|---|---|
Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial.
Topics: Aged; Amiloride; Cross-Over Studies; Diuretics; Double-Blind Method; Female; Fibrosis; Heart Disease | 2013 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Diuretics; Double-Blind Method; Drug | 1999 |
[Fluid redistribution between the extracellular medium and the cells in the diuretic therapy of cardiac insufficiency].
Topics: Adult; Aged; Body Water; Cardiac Glycosides; Clinical Trials as Topic; Coronary Disease; Diuretics; | 1975 |
45 other studies available for spironolactone and Heart Diseases
| Article | Year |
|---|---|
Aldosterone: The Missing Cardiorenal Link.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Diseases; Humans; Kidney Diseases; Mine | 2019 |
Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Dog Diseases; Dogs; Electrolytes; Hear | 2020 |
Spironolactone effect on potassium supplementation in paediatric cardiac intensive care patients.
Topics: Child, Preschool; Cohort Studies; Critical Care; Diuretics; Dose-Response Relationship, Drug; Female | 2017 |
Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism.
Topics: Animals; Atrophy; Blood Pressure; Corticosterone; Disease Models, Animal; Fibrosis; Heart Diseases; | 2013 |
Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Topics: Animals; Antibodies; Desoxycorticosterone Acetate; Disease Models, Animal; Down-Regulation; Forkhead | 2014 |
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease.
Topics: Animals; Aorta; Biomarkers; Blood Pressure; Cytoprotection; Disease Models, Animal; Disease Progress | 2015 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomark | 2015 |
Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
Topics: Action Potentials; Animals; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Collagen; Cytoprotection; | 2016 |
Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit.
Topics: Eplerenone; Heart Diseases; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Renin-Angi | 2008 |
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Topics: Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Enzyme Inhibitors; Fibrosis; Heart Diseases; Kidn | 2009 |
Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism.
Topics: Administration, Oral; Animals; Body Weight; Fibrosis; Glucocorticoids; Heart; Heart Diseases; Hemody | 2010 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats.
Topics: Animals; Fibrosis; Gene Expression Regulation, Enzymologic; Heart Diseases; Isoproterenol; Male; Mat | 2011 |
Effect of spironolactone on patients with atrial fibrillation and structural heart disease.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Elect | 2011 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Targeting activated mineralocorticoid receptor: Occam's razor revisited.
Topics: Aldosterone; Angiotensin II; Animals; Heart Diseases; Kidney Diseases; Mineralocorticoid Receptor An | 2012 |
The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction.
Topics: Anabolic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Heart Diseases; Losartan; Male; M | 2013 |
ALDOSTERONE AND THE EDEMA OF CONGESTIVE HEART FAILURE.
Topics: Aldosterone; Chromatography; Diuretics; Edema; Geriatrics; Heart Diseases; Heart Failure; Hypertensi | 1964 |
[EFFECT OF AN ALDOSTERONE ANTAGONIST IN THERAPY RESISTANT EDEMAS].
Topics: Antihypertensive Agents; Benzothiadiazines; Diuretics; Drug Therapy; Edema; Heart Diseases; Liver Ci | 1964 |
[STUDY OF THE ASSOCIATION OF A SALT DIURETIC AND A SPIRONOLACTONE. APROPOS OF 50 OBSERVATIONS].
Topics: Abdominal Neoplasms; Ascites; Benzothiadiazines; Biomedical Research; Diuretics; Edema; Heart Diseas | 1964 |
SPIRONOLACTONE THERAPY AND GYNECOMASTIA.
Topics: Drug Therapy; Geriatrics; Gynecomastia; Heart Diseases; Humans; Male; Spironolactone; Toxicology | 1965 |
Clinical experience with spironolactone in pediatrics.
Topics: Chronic Disease; Diagnosis-Related Groups; Diuretics; Female; Heart Diseases; Humans; Hyperkalemia; | 2005 |
SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.
Topics: Angiotensins; Animals; Blood Pressure; Connective Tissue Growth Factor; Desoxycorticosterone; Fibros | 2006 |
Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone.
Topics: Animals; Aorta; Blood Pressure; Blotting, Northern; Carotid Artery Diseases; Collagen; Eplerenone; F | 2006 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
[Study on the effect and tolerance of Acelate as an aldosterone antagonist].
Topics: Ascites; Edema; Female; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Spironolactone | 1982 |
Pediatric clinical pharmacology of digoxin.
Topics: Adult; Child; Digoxin; Diuretics; Drug Interactions; Furosemide; Heart; Heart Diseases; Hemoperfusio | 1981 |
Clinical studies on digoxin intoxication. I. Serum concentration of digoxin in the elderly and the effect of diuretics.
Topics: Adult; Age Factors; Aged; Blood Urea Nitrogen; Creatinine; Digoxin; Diuretics; Dose-Response Relatio | 1980 |
Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.
Topics: Aldosterone; Angiotensin II; Animals; Diet, Sodium-Restricted; Disease Models, Animal; Eplerenone; H | 2002 |
Factors influencing the choice of antihypertensive agents.
Topics: Age Factors; Aldosterone; Cerebrovascular Disorders; Clonidine; Depression; Diabetes Complications; | 1976 |
[The efficacy of spironolacton in cardiopulmonary insufficiency (author's transl)].
Topics: Animals; Bicarbonates; Blood Gas Analysis; Drug Evaluation; Guinea Pigs; Heart Diseases; Humans; Lun | 1976 |
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi | 1973 |
[Hyperkalemias in cardiac patients].
Topics: Acidosis; Acute Kidney Injury; Adult; Aged; Arrhythmias, Cardiac; Digitalis Glycosides; Diuretics; F | 1974 |
Diuretics.
Topics: Benzothiadiazines; Blood; Chlorides; Diuretics; Diuretics, Osmotic; Edema; Ethacrynic Acid; Heart Di | 1974 |
[Effect of spironolactone in experimental myocardial necrosis].
Topics: Adrenal Gland Diseases; Adrenal Glands; Animals; Female; Heart Diseases; Hyperplasia; Male; Myocardi | 1972 |
Generic non-equivalence in cardiac practice.
Topics: Anticoagulants; Digoxin; Heart Diseases; Humans; Spironolactone; Therapeutic Equivalency | 1973 |
[Use of aldactone and veroshpiron in complex therapy of patients with circulation disorders].
Topics: Adolescent; Adult; Aged; Arteriosclerosis; Calcium; Female; Heart Diseases; Humans; Hypertension; Ma | 1973 |
[New aspects of the use of spironolactone and its association with thiabutazide (per os and in injections) in the treatment of grave cardiac insufficiency].
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Benzothiadiazines; Diabetes Complications; D | 1974 |
[Rhythm disorders induced directly or by potassium depletion. General review apropos of 20 cases].
Topics: Aged; Alcoholic Intoxication; Arrhythmias, Cardiac; Cathartics; Cell Membrane; Cell Membrane Permeab | 1970 |
[Effect of antikaliuretics on the development of cardiac lesions in potassium or magnesium deficiencies in the rat].
Topics: Amiloride; Animals; Chlorides; Diet; Diuretics; Female; Heart; Heart Diseases; Magnesium; Magnesium | 1971 |
The use of glucocorticoids for diuresis in patients with fluid retention not resulting from renal disease.
Topics: Aldosterone; Chlorothiazide; Diuresis; Edema; Glomerular Filtration Rate; Glucocorticoids; Heart Dis | 1966 |
[Steroids and nephrectomy cardiopathy].
Topics: Animals; Calcinosis; Cardiovascular Diseases; Desoxycorticosterone; Estradiol; Ethylestrenol; Heart | 1970 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |
[Changes in the acid-base equilibrium in cardiac insufficiency].
Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Respiratory; Alkalosis; Bicarbonates; Heart Diseases; Hea | 1967 |
[Aldacton causing intermittent hyperkalemic muscle paralysis].
Topics: Adult; Diuretics; Female; Heart Diseases; Humans; Hyperkalemia; Paraplegia; Spironolactone | 1968 |